NIZAXID 15 MG/ML SYRUP 90 ML

Indication For the treatment of acid-reflux disorders (GERD) peptic ulcer disease active benign gastric ulcer and active duodenal ulcer. Pharmacodynamics Nizatidine is a competitive reversible inhibitor of histamine at the histamine H2-receptors particularly those in the gastric parietal cells. By inhibiting the action of histamine on stomach cells nizatidine reduces stomach acid production. Nizatidine had no demonstrable antiandrogenic action. Full-dose therapy for the problems treated by nizatidine lasts no longer than 8 weeks. It has been demonstrated that treatment with a reduced dose of nizatidine is effective as maintenance therapy following healing of active duodenal ulcers. Mechanism of action Nizatidine competes with histamine for binding at the H2-receptors on the gastric basolateral membrane of parietal cells. Competitive inhibition results in reduction of basal and nocturnal gastric acid secretions.